PMOS (A Proposed New Name for PCOS): How GLP-1 Medications May Improve Women's Hormonal and Metabolic Health
If you have been staying up-to-date with what is going on in the world of women's health, you may have recently come across a new term: Polyendocrine Metabolic Ovarian Syndrome (PMOS). If you're wondering, "Is PMOS different from PCOS?"—you're not alone. The short answer is no. PMOS is not a new disease. Instead, it is a proposed new name for the condition long known as Polycystic Ovary Syndrome (PCOS).
Many researchers and clinicians believe this new name better reflects what we now understand about the condition. Rather than being solely an ovarian disorder, PCOS affects multiple hormone systems, metabolism, and long-term health.
At this time, PCOS remains the official medical diagnosis used by healthcare organizations, clinical guidelines, insurance companies, and medical coding systems. Throughout this article, we'll primarily use the term PCOS while also introducing the proposed term PMOS so you can become familiar with both.
Why Are Experts Proposing the Name PMOS?
When PCOS was first described nearly a century ago, the condition was named for one of its visible features: enlarged ovaries containing many small follicles that can resemble cysts on ultrasound.
Over time, researchers discovered that the name doesn't tell the whole story.
In fact:
Many women diagnosed with PCOS do not have polycystic-appearing ovaries.
Some women with polycystic-appearing ovaries do not have PCOS.
The condition affects much more than reproductive health.
Today, we know that PCOS often involves changes in:
Hormone regulation
Insulin function
Metabolism
Body weight
Inflammation
Cardiovascular risk
Fertility
Liver health
The proposed term Polyendocrine Metabolic Ovarian Syndrome (PMOS) highlights these broader effects by emphasizing three key features:
Polyendocrine – Multiple hormone systems may be involved, including insulin, ovarian hormones, adrenal hormones, and brain signaling.
Metabolic – Many women experience insulin resistance, altered glucose metabolism, abnormal cholesterol, and an increased risk of type 2 diabetes and cardiovascular disease.
Ovarian – The ovaries remain an important part of the condition, contributing to irregular ovulation and elevated androgen levels in many women.
Although the terminology is evolving, the goal is the same: to better describe a condition that affects the whole body, not just the ovaries.
Understanding the Metabolic Side of PMOS/PCOS
One of the biggest advances in PCOS research has been recognizing the central role of insulin resistance. Insulin is a hormone that helps move glucose from the bloodstream into cells, where it is used for energy. When the body becomes less responsive to insulin, it produces more of it to keep blood sugar under control.
High insulin levels can stimulate the ovaries to produce more androgens (such as testosterone), which may contribute to:
Irregular menstrual cycles
Difficulty ovulating
Acne
Excess facial or body hair
Scalp hair thinning
Weight gain, particularly around the abdomen
Insulin resistance can also increase the long-term risk of:
Prediabetes and type 2 diabetes
Fatty liver disease
High blood pressure
Elevated cholesterol
Cardiovascular disease
Recognizing these metabolic changes is one of the main reasons experts believe the term PMOS better reflects the condition.
Where Do GLP-1 Medications Fit In?
GLP-1 receptor agonists, including semaglutide, and dual GIP/GLP-1 receptor agonists such as tirzepatide, were originally developed to treat type 2 diabetes and obesity. Researchers are now studying their potential role in women with PCOS because they address several of the underlying metabolic abnormalities commonly associated with the condition. These medications may help:
Improve Insulin Sensitivity - By enhancing the body's response to insulin, GLP-1 medications may reduce the high insulin levels that contribute to excess androgen production in many women with PCOS.
Support Healthy Weight Loss - Weight management can be particularly challenging for women with PCOS due to complex hormonal and metabolic factors. Clinical trials have shown that GLP-1 medications can support meaningful weight loss when combined with nutrition, physical activity, and lifestyle changes. Even modest weight loss may improve menstrual regularity, ovulation, and overall metabolic health.
Reduce Appetite and Food Noise - Many patients report fewer food cravings, improved satiety, and less preoccupation with eating, making long-term lifestyle changes easier to maintain.
Improve Overall Metabolic Health - Beyond weight loss, GLP-1 medications may improve the following. These improvements may help reduce some of the long-term health risks associated with PCOS.
Blood sugar regulation
Cholesterol levels
Blood pressure
Fatty liver disease
Inflammatory markers
What Does the Research Show?
Human clinical studies suggest that GLP-1 receptor agonists may improve several outcomes for women with PCOS, including:
Weight loss
Insulin resistance
Waist circumference
Blood sugar control
Menstrual regularity
Ovulation frequency
Cholesterol levels
Quality of life
Some studies have also observed improvements in androgen levels and fertility-related outcomes, though additional research is needed. Most published studies have evaluated liraglutide or semaglutide. Dedicated trials of tirzepatide in women with PCOS are still emerging, but researchers are optimistic because of its powerful effects on weight loss and metabolic health in other populations.
Importantly, GLP-1 medications are not currently FDA-approved specifically for PCOS, and their use for this condition is considered off-label. However, off-label prescribing is common in medicine when supported by clinical evidence and individualized patient assessment.
Frequently Asked Questions
Is PMOS officially replacing PCOS? Not yet. PMOS is a proposed new name that some experts believe better reflects the hormonal and metabolic nature of the condition. However, PCOS remains the official diagnosis used in current clinical guidelines and everyday medical practice.
Why are researchers considering a name change? Many experts feel the term "Polycystic Ovary Syndrome" does not accurately describe the condition because many women do not have ovarian cysts, while others with polycystic-appearing ovaries do not have the syndrome. The proposed term PMOS emphasizes the broader hormonal and metabolic features.
Can GLP-1 medications cure PMOS/PCOS? No. There is currently no cure. However, GLP-1 medications may help improve insulin resistance, support weight management, and reduce several symptoms and long-term health risks when used as part of a comprehensive treatment plan.
Are these medications appropriate for every woman? No. The best treatment depends on your symptoms, metabolic health, reproductive goals, medical history, and personal preferences. A personalized evaluation is essential.
What This Means for Patients
Whether you know this condition as PCOS or have recently heard the proposed term PMOS, one thing is becoming increasingly clear: this is not simply an ovarian disorder. It is a complex condition involving hormones, metabolism, insulin signaling, and long-term health.
As our understanding continues to evolve, so too do the treatment options available to women.
GLP-1 medications represent one of the most promising advances in addressing the metabolic side of PCOS, but they are only one part of a comprehensive approach that includes nutrition, movement, sleep, stress management, and individualized medical care.
At Sun Valley Natural Medicine, our goal is to help you understand both today's evidence and tomorrow's possibilities so you can make informed decisions about your health with confidence.
Selected References
International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023).
American Society for Reproductive Medicine. Evidence-based guideline for PCOS.
American Diabetes Association. Standards of Care in Diabetes.
Jensterle M, et al. GLP-1 receptor agonists in women with PCOS.
Elkind-Hirsch KE, et al. Liraglutide treatment in women with PCOS.
This article is intended for educational purposes only and should not be considered personal medical advice. Always consult your healthcare provider before starting or changing any medication.